Clinicopathological and Treatment Patterns of Combined Small-Cell Lung Carcinoma with Future Insight to Treatment: A Population-Based Study

被引:4
|
作者
Ullah, Asad [1 ]
Saeed, Omer [2 ]
Karki, Nabin Raj [3 ]
Goodbee, Mya [4 ]
Yasinzai, Abdul Qahar Khan [5 ]
Waheed, Abdul [6 ]
Heneidi, Saleh [7 ]
Thomas, Anish [8 ]
Karim, Nagla Abdel [9 ]
Johnson, Joyce [1 ]
Del Rivero, Jaydira [8 ]
Khan, Jaffar [2 ]
机构
[1] Vanderbilt Univ Sch Med, Dept Pathol, Nashville, TN 37232 USA
[2] Indiana Univ, Indiana Sch Med, Dept Pathol, Indianapolis, IN 46202 USA
[3] Univ S Alabama, Dept Hematol & Oncol, Mobile, AL 36688 USA
[4] Augusta Univ, Med Coll Georgia, Augusta, GA 30912 USA
[5] Bolan Med Coll, Dept Med, Quetta 83700, Pakistan
[6] San Joaquin Gen Hosp, Dept Surg, San Joaquin, CA 95231 USA
[7] Cedars Sinai Med Ctr, Dept Mol Pathol, Los Angeles, CA 90048 USA
[8] Natl Inst Hlth NIH, Dept Hematol & Oncol, Bethesda, MD 20814 USA
[9] Inova Schar Canc Inst, Dept Hematol & Oncol, Fairfax, VA 22031 USA
关键词
combined small cell; lung cancer; histology; chemotherapy; molecular changes; CANCER; SCLC;
D O I
10.3390/jcm12030991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Primary lung cancer is the most common cause of cancer-related mortality in the United States (US). Approximately 90% of lung cancers are associated with smoking and the use of other tobacco products. Based on histology, lung cancers are divided into small-cell lung carcinomas (SCLCs) and non-small-cell lung carcinomas (NSCLCs). Most SCLCs are of the pure subtype, while the rare combined SCLCs contain elements of both small-cell and non-small-cell morphologies. This study sought to evaluate the demographics, clinical factors, molecular abnormalities, treatment approaches, and survival outcomes with combined SCLC and NSCLCs. Materials and Methods: Data on 2126 combined SCLC patients was extracted from the Surveillance Epidemiology and End Result (SEER) database from 2000 to 2018. Data extracted for analyses included age, sex, race, tumor size, tumor location, metastasis status, stage at diagnosis, treatment received, and treatment outcomes. Multivariate analysis was performed using Statistical Product and Service Solutions (SPSS) software. Results: The patients had a median age of 68 years; 43.9% of the patients were female and 56.1% were male; 84.5% were White and 11.7% were African Americans. The majority of patients had a poorly differentiated disease at 29.6%; 17% were undifferentiated, 3.2% were moderately differentiated, and 0.8% were well differentiated. Chemotherapy was the most common treatment modality (45.3%); 17% underwent surgery only, 10.3% underwent surgery followed by adjuvant chemotherapy, and 10% underwent radiation after surgery. Five-year cancer-specific survival was 15.2% with surgery alone, and combined surgery and chemotherapy provided the highest percentages (38.3% and 34.7%, respectively). Females had significantly higher 1- and 5-year cancer-specific survival rates compared to males (59.3% and 29.9% vs. 48.0% and 23.7, respectively; p < 0.001). Well-differentiated tumors had significantly higher survival compared to other gradings (p < 0.001). Survival decreased as tumor staging moved distally from localized to regional to distant (p < 0.001). Metastasis to bone, liver, brain, and lung significantly decreased survival in comparison to patients who did not have any metastasis (p < 0.001). Females had significantly shorter survival compared to their counterparts when metastasis was to the bone, brain, or liver (p < 0.001). Multivariate analysis identified male sex (Hazard Ratio (HR) = 1.2), undifferentiated grade (HR = 1.9), regional extent of disease (HR = 1.7), distant extent of disease (HR = 3.7), and metastasis to liver (HR = 3.5) as variables associated with worse survival. Conclusion: Combined SCLC is overall very rare. However, the frequency of presentation with combined SCLC is on the rise, in part due to improvements in diagnostic techniques. Despite advances in therapies, treating combined SCLC is challenging, and novel therapies are not utilized, owing to low rates of targetable mutations. Combined SCLC has higher survival rates if well differentiated.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Prognostic impact of metastatic patterns and treatment modalities on overall survival in lung squamous cell carcinoma: A population-based study
    Qin, Lang
    Yu, Xiangtian
    Xu, Chuang
    Liu, Yangchen
    MEDICINE, 2023, 102 (29) : E34251
  • [32] HERPES-ZOSTER IN PATIENTS WITH SMALL-CELL CARCINOMA OF THE LUNG RECEIVING COMBINED MODALITY TREATMENT
    FELD, R
    EVANS, WK
    DEBOER, G
    ANNALS OF INTERNAL MEDICINE, 1980, 93 (02) : 282 - 283
  • [33] Clinicopathological Characteristics and Survival of Small Cell Carcinoma of the Salivary Gland: a Population-Based Study
    Bai, Jinbo
    Zhao, Fen
    Pan, Shuang
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10749 - 10757
  • [34] Educational Level and Management in Small-Cell Lung Cancer (SCLC): A Population-Based Study
    Tendler, Salomon
    Holmqvist, Marit
    Wagenius, Gunnar
    Lewensohn, Rolf
    Viktorsson, Kristina
    De Petris, Luigi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S723 - S724
  • [35] Treatment of small-cell lung cancer
    Mennecier, B
    Dansin, E
    REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (01) : 171 - 174
  • [36] Treatment of small-cell lung cancer
    Reck, M.
    Bohnet, S.
    INTERNIST, 2011, 52 (02): : 130 - +
  • [37] Treatment for small-cell lung cancer
    Saadeen, Ahmed
    Jazieh, Abdul-Rahman
    ANNALS OF THORACIC MEDICINE, 2008, 3 (06) : S100 - S103
  • [38] TREATMENT OF SMALL-CELL CARCINOMA OF BRONCHUS
    TATTERSALL, S
    RYALL, RDH
    LANCET, 1975, 1 (7904): : 451 - 452
  • [39] TREATMENT OF SMALL-CELL CARCINOMA OF BRONCHUS
    LAING, AH
    BERRY, RJ
    NEWMAN, CR
    SMITH, P
    LANCET, 1975, 1 (7899): : 129 - 132
  • [40] TREATMENT OF SMALL-CELL CARCINOMA OF BRONCHUS
    MUGGIA, FM
    HANSEN, HH
    DOMBERNOWSKY, P
    LANCET, 1975, 1 (7908): : 692 - 692